Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges
Eli Lilly raised its full-year revenue forecast to $91B-$92B, citing strong sales of weight-loss drugs Mounjaro and Zepbound, which beat expectations. Adjusted profit outlook was trimmed to $35.00-$36.00 per share due to acquisition-related charges. Third-quarter revenue was $24.4B, exceeding estimates, with Mounjaro and Zepbound sales also surpassing expectations.
How this was made
The 30-second read
Why it matters
The guidance raise and sales beats are likely to drive re-rating for Lilly’s GLP-1 franchise, while the trimmed adjusted profit outlook and disclosed realized price declines keep margin risk in focus.
Market read
This is a company-specific earnings and guidance update for the GLP-1 leader, with explicit revenue and adjusted profit outlook changes and product-level sales drivers.
What to watch
Foundayo oral rollout is a key test versus Novo Nordisk’s oral Wegovy; early prescription lag and future discounting could affect longer-term margin trajectory.
Background
Lilly is competing in the GLP-1 obesity market against Novo Nordisk, with investors focused on pricing durability in US government health plans and the transition from injectable to oral therapies.
Ticker impact
Eli Lilly raised full-year revenue guidance to $91B-$92B and beat Q3 earnings, citing surging injectable weight-loss demand and trimmed profit outlook from deal charges.
Likely upward bias as investors reprice growth in injectable weight-loss, partially offset by concerns about adjusted profit pressure from deal-related charges and pricing dynamics.
The article reports new, company-specific guidance and Q3 results with explicit drivers (Mounjaro and Zepbound sales strength) plus a concrete profit outlook trim tied to third-quarter acquisition charges.
Market effects
Reinforces demand strength in the GLP-1 obesity market and may reduce near-term fears of US government plan price erosion for the sector.
US Medicare coverage pilot and realized price declines highlight ongoing reimbursement and pricing pressure that can influence sector multiples.
International reimbursement dynamics (eg, China list inclusion) remain a key swing factor for realized pricing and growth expectations.
Counterpoint
The revenue beat may not fully translate into sustained adjusted EPS upside because realized prices fell and adjusted profit guidance was trimmed due to acquisition charges.
Key entities
- companyEli Lilly
Raised full-year revenue outlook and reported Q3 beats, driven by injectable weight-loss demand; trimmed adjusted profit view due to acquisition-related charges.
- companyNovo Nordisk
Named as Danish rival in the GLP-1 market; investors compare Lilly’s progress versus Novo’s first-mover advantage.
- companyAtaiBeckley
Acquisition referenced as a source of third-quarter acquired research charges impacting adjusted profit guidance.
- companyCurevo
Acquisition referenced as a source of third-quarter acquired research charges impacting adjusted profit guidance.
- productMounjaro
Diabetes drug sales reported at $10.72B in Q3, contributing to overall revenue strength.
